Michael Hayden

Michael R.
Hayden founded Aspreva Pharmaceuticals Corp.
in 2002, where he worked as Director from 2002 to 2007, Centre for Molecular Medicine & Therapeutic in 1992, where he worked as Director from 1992 to 2012, Xenon Pharmaceuticals, Inc. in 1996, where he worked as Independent Director from 2012 to 2022, and 89bio, Inc. in 2018, where he worked as Independent Director from 2018 to 2025.
Dr. Hayden also founded NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd., and Prilenia Therapeutics BV, where he is working as Chief Executive Officer.
Dr. Hayden also currently works at Ionis Pharmaceuticals, Inc., as Independent Director from 2018, National University of Singapore, as Director-Translational Laboratory, Canadian Genetics Diseases Network, as Scientific Director from 1990, Royal Society of Canada, as Director from 1995, AbCellera Biologics, Inc., as Lead Independent Director from 2019, Translational Laboratory in Genetic Medicine, as Director & Program Director, Andera Partners SCA, as Venture Advisor from 2018, the University of British Columbia, as Professor from 1991, Forbion Capital Partners Management Holding BV, as Venture Partner from 2022, and American Society of Clinical Investigation, as Member from 1992.
Dr. Hayden also formerly worked at Lycera Corp., as Director, Many Bright Ideas Technologies, Inc., as Director in 2010, Agency for Science, Technology & Research, as Director, Michael Smith Foundation for Health Research, as Director from 2011 to 2012, Aurinia Pharmaceuticals, Inc., as Independent Director from 2018 to 2021, Oxford Biomedica Plc, as Non-Executive Director from 2021 to 2024, Teva Pharmaceutical Industries Ltd., as Chief Scientific Officer from 2013 to 2017, American Society of Human Genetics, as Member from 1994 to 2010, and GlobaR&D Co. ,Ltd, as President & Chief Scientific Officer.
Dr. Hayden received his undergraduate degree in 1975 and doctorate degree in 1979 from the University of Cape Town.